Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aeglea BioTherapeutics Q2 EPS $(2.27) Misses $(0.15) Estimate, Sales $688.00K Beat $200.00K Estimate

Author: Benzinga Newsdesk | August 11, 2023 07:08am
Aeglea BioTherapeutics (NASDAQ:AGLE) reported quarterly losses of $(2.27) per share which missed the analyst consensus estimate of $(0.15) by 1413.33 percent. This is a 740.74 percent decrease over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $688.00 thousand which beat the analyst consensus estimate of $200.00 thousand by 244.00 percent. This is a 10.08 percent increase over sales of $625.00 thousand the same period last year.

Posted In: AGLE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist